FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 623 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Celebrate with Us! Vaccine Rollouts Mark the Light at the End... March 8, 2021 Belzutifan Shows a Significant Benefit Over Everolimus in Patients with Advanced... August 30, 2024 Keeping progress in oncology on the agenda: ESMO honours recipients of... December 3, 2020 FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular... July 31, 2024 Load more HOT NEWS Outcomes From Second-Line Chemotherapy in Patients with Cholangiocarcinoma and FGFR2 Fusions What the Reignited Cancer Moonshot Initiative Means for People With Cancer Giving Myself the Most Time and Best Chance at Beating Cancer:... Lessons from the green: How sports psychology helped a top golf...
